A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our products are developed with customized and evolved adeno-associated virus (“AAV”) vectors invented from our proprietary synthetic vector discovery platform, Therapeutic Vector Evolution (“TVE”). TVE was designed to invent AAV vectors with properties that overcome the limitations of conventional AAV vectors by applying the principles of directed evolution in non-human primate (“NHP”) models to select vectors that target tissues of diseases with high unmet need using routine routes of administration. We have developed clinical-stage product candidates based on three vectors invented with TVE and believe the clinical results to date validate the platform.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 120K | - | - | - | - | - |
| Net Income | -209M | -161M | -101M | -107M | -71M | -57M |
| EPS | $-3.75 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | $-8.82 |
| Free Cash Flow | -185M | -138M | -79M | -98M | -78M | -52M |
| ROIC | -284.7% | -31.5% | -32.8% | -46.5% | -22.3% | -22.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.10 | 0.10 | 0.13 | 0.11 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -230M | -188M | -113M | -110M | -71M | -57M |
| Operating Margin | -191982.5% | - | - | - | - | - |
| ROE | -56.7% | -39.3% | -32.8% | -46.5% | -22.3% | -22.1% |
| Shares Outstanding | 57M | 54M | 39M | 32M | 28M | 32M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 120K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -51M | -57M | -71M | -110M | -113M | -188M | -230M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -191982.5% |
| Net Income | -49M | -57M | -71M | -107M | -101M | -161M | -209M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -174314.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -68.9% | -22.1% | -22.3% | -46.5% | -32.8% | -31.5% | N/M |
| ROE | N/A | -22.1% | -22.3% | -46.5% | -32.8% | -39.3% | -56.7% |
| ROA | -84.7% | -19.7% | -20.2% | -41.1% | -29.7% | -35.7% | -49.3% |
| Cash Flow | |||||||
| Op. Cash Flow | -37M | -51M | -69M | -87M | -76M | -135M | -183M |
| Free Cash Flow | -40M | -52M | -78M | -98M | -79M | -138M | -185M |
| Owner Earnings | -41M | -57M | -84M | -106M | -100M | -165M | -214M |
| CapEx | 3.2M | 1.0M | 9.1M | 12M | 2.8M | 3.8M | 1.6M |
| Maint. CapEx | 1.0M | 1.4M | 1.5M | 2.4M | 4.2M | 4.7M | 4.7M |
| Growth CapEx | 2.2M | 0 | 7.6M | 9.1M | 0 | 0 | 0 |
| D&A | 1.0M | 1.4M | 1.5M | 2.4M | 4.2M | 4.7M | 4.7M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.5M | 5.0M | 14M | 17M | 20M | 26M | 26M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -305M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 305M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.39 | 0.12 | 0.11 | 0.13 | 0.10 | 0.10 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -73M | 256M | 319M | 231M | 308M | 511M | 369M |
| Total Assets | 58M | 288M | 353M | 262M | 340M | 560M | 424M |
| Total Liabilities | 28M | 32M | 34M | 31M | 32M | 50M | 55M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -79M | -136M | -207M | -314M | -415M | -576M | -576M |
| Working Capital | 40M | 266M | 240M | 205M | 278M | 406M | 406M |
| Current Assets | 53M | 283M | 256M | 221M | 297M | 435M | 435M |
| Current Liabilities | 13M | 17M | 16M | 16M | 19M | 29M | 29M |
| Per Share Data | |||||||
| EPS | -9.59 | -8.82 | -2.57 | -3.32 | -2.58 | -2.98 | -3.75 |
| Owner EPS | -1.55 | -1.78 | -3.04 | -3.28 | -2.55 | -3.06 | -3.75 |
| Book Value | -2.73 | 7.95 | 11.50 | 7.14 | 7.88 | 9.46 | 6.46 |
| Cash Flow/Share | -1.38 | -1.58 | -2.49 | -2.68 | -1.94 | -2.49 | -3.58 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 26.7M | 32.2M | 27.7M | 32.4M | 39.1M | 54.0M | 57.1M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -2.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.4 | 1.9 | 3.0 | 2.7 | 0.6 | 1.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -3.7% | -13.1% | -14.1% | -9.6% | -46.2% | -33.5% |
| Market Cap | N/A | 1.4B | 598M | 699M | 821M | 300M | 552M |
| Avg. Price | N/A | 41.24 | 32.12 | 12.53 | 16.97 | 18.77 | 9.66 |
| Year-End Price | N/A | 42.97 | 21.54 | 21.59 | 21.01 | 5.55 | 9.66 |
4D Molecular Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
4D Molecular Therapeutics, Inc. (FDMT) has a 5-year average return on invested capital (ROIC) of -31.0%. This is below average and may indicate limited pricing power.
4D Molecular Therapeutics, Inc. (FDMT) has a market capitalization of $552M. It is classified as a small-cap stock.
4D Molecular Therapeutics, Inc. (FDMT) does not currently pay a regular dividend.
4D Molecular Therapeutics, Inc. (FDMT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
4D Molecular Therapeutics, Inc. (FDMT) generated $-138 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
4D Molecular Therapeutics, Inc. (FDMT) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
4D Molecular Therapeutics, Inc. (FDMT) reported earnings per share (EPS) of $-2.98 in its most recent fiscal year.
4D Molecular Therapeutics, Inc. (FDMT) has a return on equity (ROE) of -39.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for 4D Molecular Therapeutics, Inc. (FDMT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
4D Molecular Therapeutics, Inc. (FDMT) has a book value per share of $9.46, based on its most recent annual SEC filing.